Chordoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:178OMIM:215400C76.7
Who is this for?
Show terms as
14Active trials37Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Chordoma is a rare type of bone cancer that grows from leftover cells of the notochord, a structure that helps form the spine in a developing embryo. These cells normally disappear before birth, but in some people, small clusters remain and can eventually turn into a tumor. Chordomas almost always occur along the spine, most commonly at the base of the skull (called the clivus) or at the bottom of the spine (the sacrum or tailbone area). They can also appear in the vertebrae of the neck or back, though this is less common. Chordomas are slow-growing tumors, but they are locally aggressive, meaning they tend to invade nearby bone and soft tissue. They can press on important structures like the brain, spinal cord, or nerves, causing pain, numbness, weakness, or problems with bladder and bowel function depending on their location. Skull base chordomas may cause headaches, double vision, or difficulty swallowing. The main treatment for chordoma is surgery to remove as much of the tumor as possible, often followed by specialized radiation therapy such as proton beam therapy. Because chordomas tend to come back after treatment, long-term follow-up is essential. Chemotherapy has generally not been very effective for chordoma, though targeted therapies are being studied in clinical trials. Despite being slow-growing, chordomas can be difficult to cure completely because of their location near critical structures in the body.

Also known as:

Key symptoms:

Pain at the base of the spine or tailboneHeadachesDouble vision or blurred visionDifficulty swallowingChanges in voice or hoarsenessNumbness or tingling in the arms or legsWeakness in the arms or legsLoss of bladder controlLoss of bowel controlA noticeable lump or mass near the tailboneNeck pain or stiffnessFacial pain or numbnessDifficulty walking or balance problemsLower back pain that does not go away

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Apr 2025A Study of ERAS-601 in People With Chordoma

Memorial Sloan Kettering Cancer Center — PHASE1, PHASE2

TrialRECRUITING
Jan 2025A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma

Sichuan Baili Pharmaceutical Co., Ltd. — PHASE2

TrialRECRUITING
Jan 2025Pembrolizumab and Pemetrexed for Progressive Chordoma

Saint John's Cancer Institute — PHASE2

TrialRECRUITING
Jun 2024Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

TrialRECRUITING
Sep 2023Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy

Centre Antoine Lacassagne — NA

TrialRECRUITING
May 2022Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma

M.D. Anderson Cancer Center — PHASE2

TrialACTIVE NOT RECRUITING
Apr 2022Multi-parametric Imaging in Personalized Radiotherapy

CNAO National Center of Oncological Hadrontherapy

TrialRECRUITING
Feb 2021Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas

Leiden University Medical Center

TrialRECRUITING
May 2019Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Sarcoma Oncology Research Center, LLC — PHASE2

TrialRECRUITING
Apr 2019Children and Adults With Chordoma

National Cancer Institute (NCI) — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Chordoma.

14 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

14 recruitingView all trials with filters →
Phase 25 trials
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
Phase 2
Actively Recruiting
· Sites: Guangzhou, Guangdong · Age: 1875 yrs
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
Phase 2
Actively Recruiting
PI: Sant P Chawla, MD (Sarcoma Oncology Center) · Sites: Santa Monica, California · Age: 1899 yrs
Proton Beam Therapy for Chordoma Patients
Phase 2
Active
PI: David Grosshans, MD, PHD (M.D. Anderson Cancer Center) · Sites: Houston, Texas
Pembrolizumab and Pemetrexed for Progressive Chordoma
Phase 2
Actively Recruiting
· Sites: Santa Monica, California · Age: 1899 yrs
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
Phase 2
Active
PI: Anthony P Conley, MD (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 1899 yrs
Phase 11 trial
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
Phase 1
Active
PI: Lawrence Kleinberg, MD (Johns Hopkins University/Sidney Kimmel Cancer Cent) · Sites: Baltimore, Maryland; New York, New York · Age: 1599 yrs
N/A4 trials
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
N/A
Actively Recruiting
PI: Alessandro Gronchi, MD (Istituto Nazionale Tumori Milan-Italy) · Sites: Graz; Wiener Neustadt, Österreich +26 more · Age: 1880 yrs
Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors
N/A
Actively Recruiting
PI: Pascal POMMIER, MD (Centre Leon Berard) · Sites: Amiens; Caen +19 more · Age: 1899 yrs
Children and Adults With Chordoma
N/A
Actively Recruiting
PI: Mary F Wedekind Malone, D.O. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 299 yrs
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
N/A
Actively Recruiting
· Sites: Nice · Age: 1899 yrs
Other3 trials
Multi-parametric Imaging in Personalized Radiotherapy
Actively Recruiting
PI: Alberto Iannalfi, MD (CNAO National Center of Oncological Hadrontherapy) · Sites: Pavia, Pv · Age: 1899 yrs
Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma
Actively Recruiting
PI: Kristin Redmond, MD, MPH (Sidney Kimmel Comprehensive Cancer Center at Johns) · Sites: Baltimore, Maryland; Philadelphia, Pennsylvania · Age: 1899 yrs
Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas
Actively Recruiting
PI: Stijn Krol, MD PhD (LUMC/HollandPTC) · Sites: Delft, South Holland; Leiden, South Holland · Age: 5099 yrs

Specialists

Showing 25 of 37View all specialists →
GM
Gregory Cote, MD
BOSTON, MA
Specialist
PI on 1 active trial1 Chordoma publication
RM
Ronny L Rotondo, MD
KANSAS CITY, KS
Specialist
PI on 1 active trial
KM
Kristin Redmond, MD, MPH
Specialist
PI on 1 active trial
AM
Anthony P Conley, MD
HOUSTON, TX
Specialist
PI on 1 active trial1 Chordoma publication
HM
Hamid MAMMAR, MD
Specialist
PI on 1 active trial
TM
Thomas F. DeLaney, MD
Specialist
PI on 2 active trials
GM
Georgia KARPATHIOU, MD
Specialist
PI on 1 active trial1 Chordoma publication
MM
Mrinal Gounder, MD
NEW YORK, NY
Specialist
PI on 3 active trials
SP
Scott Schuetze, MD, PhD
ANN ARBOR, MI
Specialist
PI on 3 active trials
SM
Sant P Chawla, MD
SANTA MONICA, CA
Specialist
PI on 5 active trials
SP
Sandip P Patel
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 1 active trial
SM
Suzanne Forrest, MD
Specialist
PI on 1 active trial
BM
Bradford S. Hoppe, MD, MPH
JACKSONVILLE, FL
Specialist
PI on 2 active trials
SD
Stefan Fröhling, Prof. Dr.
Specialist
PI on 2 active trials
LM
Lawrence Kleinberg, MD
BALTIMORE, MD
Specialist
PI on 2 active trials1 Chordoma publication
AP
Alisa M Goldstein, Ph.D.
PITTSBURGH, PA
Specialist
PI on 3 active trials
MM
Mary F Wedekind Malone
Specialist
PI on 1 active trial18 Chordoma publications
AP
AJ Gelderblom, Prof
Specialist
PI on 2 active trials
JM
Jordan Milner, MD
GAINESVILLE, FL
Specialist
PI on 5 active trials
TP
Timothy Cripe, M.D., PhD.
COLUMBUS, OH
Specialist
PI on 1 active trial
MM
Mary (Nora) L Disis, MD
SEATTLE, WA
Specialist
PI on 1 active trial
PM
Pascal POMMIER, MD
Specialist
PI on 1 active trial
MD
Mary F Wedekind Malone, D.O.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 3 active trials
EP
Edwin Choy, MD, PhD
BOSTON, MA
Specialist
PI on 3 active trials

Treatment Centers

8 centers
⚗️ Trial Site

National Institutes of Health Clinical Center

📍 Bethesda, Maryland

👤 Payal P Khincha, M.D.

👤 Christopher Grunseich, M.D.

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

Travel Grants

No travel grants are currently matched to Chordoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open ChordomaForum →

No community posts yet. Be the first to share your experience with Chordoma.

Start the conversation →

Latest news about Chordoma

1 articles
Clinical trialCLINICALTRIALSMar 26, 2026
New Clinical Trial: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (NCT02834013)
Researchers are testing two cancer-fighting drugs called nivolumab and ipilimumab together to treat patients with rare types of cancer. These drugs help the bod
See all news about Chordoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What is the exact location and size of my chordoma, and has it spread?,Is complete surgical removal possible, and what are the risks of surgery in my case?,Do you recommend proton beam radiation therapy, and where is the nearest center that offers it?,Are there any clinical trials I might be eligible for?,What is the likelihood that my chordoma will come back after treatment?,How will treatment affect my bladder, bowel, and sexual function?,Should my family members be tested for genetic risk factors for chordoma?

Common questions about Chordoma

What is Chordoma?

Chordoma is a rare type of bone cancer that grows from leftover cells of the notochord, a structure that helps form the spine in a developing embryo. These cells normally disappear before birth, but in some people, small clusters remain and can eventually turn into a tumor. Chordomas almost always occur along the spine, most commonly at the base of the skull (called the clivus) or at the bottom of the spine (the sacrum or tailbone area). They can also appear in the vertebrae of the neck or back, though this is less common. Chordomas are slow-growing tumors, but they are locally aggressive, me

How is Chordoma inherited?

Chordoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Chordoma typically begin?

Typical onset of Chordoma is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Chordoma?

Yes — 14 recruiting clinical trials are currently listed for Chordoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Chordoma?

25 specialists and care centers treating Chordoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.